Brief: Targovax Announces Effects On Non-Injected Lesions In ONCOS-102 Trial In Anti-PD1 Refractory Melanoma Patients

Circio Holding ASA

02/12/2020 01:15

Dec 1 (Reuters) - Targovax ASA  TRVX.OL :
    * TARGOVAX ANNOUNCES IMPRESSIVE OBJECTIVE RESPONSES AS WELL
AS
EFFECTS ON NON-INJECTED LESIONS IN ONCOS-102 TRIAL IN ANTI-PD1
REFRACTORY MELANOMA PATIENTS
    * SYSTEMIC EFFECTS OBSERVED IN MULTIPLE PATIENTS, INCLUDING
TWO
EXAMPLES WHERE A NON-INJECTED LESION COMPLETELY REGRESSED

Source text for Eikon:  ID:nWkr1QH030 
Further company coverage:  TRVX.OL 

 ((Reuters.Briefs@thomsonreuters.com;))